Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.

"CONFLICT OF INTEREST Marcia S. Brose has received honoraria from Bayer, Eisai, and Lilly; has a consulting or advisory role with Bayer, Blueprint Medicines, Eisai, Exelixis, Lilly, and Loxo; and has received institutional research funding from Bayer, Blueprint Medicines, Eisai, Exelixis, Lilly, and Loxo. Bruce G. Robinson has leadership roles with Cochlear and Mayne Pharma; has stock and other ownership interests in Cochlear and Mayne Pharma; has a consulting or advisory role with Eisai and Loxo; has participated in speakers’ bureaus with Eisai; and has received travel support, accommodations, or other expenses from Eisai. Steven I. Sherman has received honoraria from Eisai; has a consulting or advisory role with Exelixis, Lilly, and Loxo; and has received institutional research funding from Exelixis. Barbara Jarzab has received honoraria from Sanofi; has a consulting or advisory role with AstraZeneca, Ewopharma, and Ipsen; has participated in speakers’ bureaus with Exelixis; has acted as an independent contractor for Amgen, Eisai, Pfizer, Lilly, Sobi, and Oxigene; and has received travel support, accommodations, or other expenses from Edomed, Ipsen, Novartis, Bayer, Sobi, and Sanofi. Chia‐Chi Lin has received honoraria from Daiichi Sankyo, Lilly, Novartis, and Roche; has a consulting or advisory role with Blueprint Medicines, Boehringer Ingelheim, Daiichi Sankyo, and Novartis; has acted as an independent contractor for Bristol‐Myers Squibb, EMD Serono, BeiGene, and AbbVie; and has received travel support, accommodations, or other expenses from BeiGene, Daiichi Sankyo, Lilly, and Novartis. Fernanda Vaisman has a consulting or advisory role with Bayer HealthCare and Merck. Ana O. Hoff has received honoraria from Bayer (continuing medical education), Genzyme (continuing medical education), and United (continuing medical education); has a consulting or advisory role with Exelixis, Lilly, and Bayer; and has received institutional research funding from Exelixis and Lilly. Daniel W. Bowles has a consulting or advisory role with Exelixis. Suvajit Sen is an employee of Exelixis and has stock and other ownership interests with Exelixis. Jennifer W. Oliver is an employee of Exelixis and has stock and other ownership interests with Exelixis. Kamalika Mukherjee is an employee of Exelixis and has stock and other ownership interests with Exelixis. Bhumsuk Keam has received honoraria from AstraZeneca, Merck, and MSD Oncology; has a consulting or advisory role with ABL Bio, AstraZeneca, CbsBioscience, Cellid, Genexine, Handok, and MSD Oncology; and has received research funding from AstraZeneca, MSD Oncology, and Ono Pharmaceutical. Jaume Capdevila has a consulting or advisory role with Advanced Accelerator Applications, Bayer, Eisai, Exelixis, Ipsen, Lilly, Merck Serono, Novartis, Pfizer, Sanofi, and Vall Hebron; has participated in speakers’ bureaus with Bayer, Eisai, Ipsen, Lilly, Merck Serono, Novartis, Pfizer, and Sanofi; and has received institutional research funding from Advanced Accelerator Applications, AstraZeneca, Bayer, Eisai, Ipsen, Lilly, Novartis, and Pfizer. The other authors made no disclosures."

"This study was sponsored by Exelixis, Inc., (Alameda, California). We thank the patients and their families, the investigators, and the site staff. Writing and editorial assistance was provided by Alexus Rivas, PharmD, and Michael Raffin (Fishawack Communications, a part of Fishawack Health, Conshohocken, Pennsylvania) and was funded by Exelixis."

"The study protocol was approved by the institutional review board or ethics committee at each center. The trial was performed in compliance with Good Clinical Practice, including the International Conference on Harmonization and the Declaration of Helsinki. All patients provided written informed consent. This trial is registered with ClinicalTrials.gov (NCT03690388). This trial has been registered at ClinicalTrials.gov (NCT03690388)."